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A B S T R A C T
Background
Colloids are widely used in the replacement of fluid volume. However doubts remain as to which colloid is best. Different colloids vary
in their molecular weight and therefore in the length of time they remain in the circulatory system. Because of this and their other
characteristics, they may differ in their safety and efficacy.
Objectives
To compare the effects of different colloid solutions in patients thought to need volume replacement.
Search strategy
We searched the Cochrane Injuries Group specialised register, the Cochrane Controlled Trials Register (2002 Issue 3), MEDLINE
(1994-2002/07), EMBASE (1974-2002 August week 1), and the National Research Register (2002 issue 3). Bibliographies of trials
retrieved were searched, and drug companies manufacturing colloids were contacted for information. The search was last updated in
September 2002.
Selection criteria
Randomised and quasi-randomised trials comparing colloid solutions in critically ill and surgical patients thought to need volume
replacement. The main outcomes measured were death, amount of whole blood transfused, and incidence of adverse reactions.
Data collection and analysis
Two authors independently extracted the data and assessed the quality of the trials.
Main results
Fifty-seven trials met the inclusion criteria, with a total of 3659 participants. Quality of allocation concealment was judged to be
adequate in 20 trials and poor or uncertain in 37.
Deaths were obtained from 36 trials. For albumin or PPF versus hydroxyethyl starch (HES) 20 trials (n=1029) reported mortality. The
pooled relative risk (RR) was 1.17 (95% CI 0.91, 1.50). For albumin or PPF versus gelatin four trials (n=542) reported mortality. The
RR was 0.99 (0.69, 1.42). For gelatin vs HES 11 trials (n=945) reported mortality, RR was 1.00 (0.78,1.28). RR was not estimable in
the albumin vs dextran, gelatin vs dextran, and HES vs dextran groups.
Thirty-six trials recorded the amount of blood transfused, however quantitative analysis was not possible due to skewness and variable
reporting. Fifteen trials recorded adverse reactions, but none occurred.
Authors’ conclusions
From this review, there is no evidence that one colloid solution is more effective or safe than any other, although the confidence intervals
are wide and do not exclude clinically significant differences between colloids. Larger trials of fluid therapy are needed if clinically
significant differences in mortality are to be detected or excluded.
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P L A I N L A N G U A G E S U M M A R Y
No strong evidence to be certain of the safety of any particular type of colloid solution for replacing blood fluids
When a person is bleeding heavily, the loss of fluid volume in their veins can lead to shock, so they need fluid resuscitation. Colloids
and crystalloids are two types of solutions used to replace lost blood fluid (plasma). They include blood and synthetic products. Both
types appear to be similarly effective at resuscitation, but one type of colloid (human albumin) was found by another Cochrane review
to increase deaths. Different colloids may have different effects. However, the review of trials found there is not enough evidence to be
sure that any particular colloid is safer than any other
B A C K G R O U N D
Colloids are used as plasma substitutes for short-term replacement
of fluid volume, while the cause of the problem is being addressed
(e.g. stopping bleeding). These solutions can be blood products
(human albumin solution, plasma protein fraction [PPF]) or syn-
thetic (modified gelatins, dextrans, etherified starches). Colloid so-
lutions are widely used in fluid resuscitation (Yim 1995) and they
have been recommended in a number of resuscitation guidelines
and intensive care management algorithms (Armstrong 1994; Ver-
meulen1995). Previous systematic reviews have suggested that col-
loids are no more effective than crystalloids in reducing mortality
(Schierhout 2000), and that albumin administration may increase
mortality compared to crystalloids or no fluid in a range of uses
(CIGAR 2000). Despite this, colloid solutions are still widely used
as they are thought to remain in the intravascular space for longer
than crystalloids and, therefore, be more effective in maintaining
osmotic pressure.
It is plausible that colloids may vary in their safety and effective-
ness. Different colloids vary in the length of time they remain
in the circulatory system. It may be that some low to medium
molecular weight colloids (e.g. gelatins and albumin) are more
likely to leak into the interstitial space (Traylor 1996), whereas
some larger molecular weight hydroxyethyl starches are retained
for longer (Boldt 1996). In addition it is thought that some col-
loids may effect coagulation or cause other adverse effects.
The previous review of colloids against crystalloids only allows in-
direct comparison of the different colloids. This review examines
direct comparisons of the different colloid solutions in randomised
trials to complement the earlier reviews on colloids compared
to crystalloids (Schierhout 2000) and human albumin (CIGAR
2000).
O B J E C T I V E S
To quantify the relative effects on mortality of different colloid
solutions in critically ill and surgical patients requiring volume re-
placement, by examining direct comparisons of colloid solutions.
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
Randomised and quasi-randomised (e.g. allocation by hospital
number or alternation) controlled trials.
Types of participants
Patients clinically assessed as requiring volume replacement or
maintenance of colloid osmotic pressure. Administration of fluid
for preoperative haemodilution or volume loading, during plasma
exchange, for priming extracorporeal circuits or following para-
centesis are excluded.
Types of intervention
The colloid solutions considered are human albumin solutions,
plasma protein fraction, modified gelatins, dextran 70, or etheri-
fied starch solutions.
Trials of other blood products not used primarily for volume re-
placement (e.g. fresh frozen plasma, pooled serum) were excluded.
The review compares the administration of any regimens of dif-
ferent classes of colloids with each other.
Types of outcome measures
The primary outcome measure is mortality from any cause at the
end of the study period. We also attempted to find data on in-
cidence of adverse reactions, allergies or anaphylactic shock, and
the amount of blood (whole blood or red blood cells) transfused
in each group. Some of the synthetic colloids may have anticoagu-
lant properties and, therefore, we felt that some measure of blood
loss or haemorrhage was important. However, as blood loss is too
vulnerable to measurement error, we decided to use the amount
of blood products transfused as an outcome measure.
Intermediate physiological outcomes were not used for several rea-
sons. These were that they are subject to intra- and inter-observer
variation, they have no face value to patients and relatives, and the
ones seen as appropriate are not stable over time. Also there would
need to exist a strong predictive relationship between the variable
and mortality.
2Colloid solutions for fluid resuscitation (Review)
Copyright © 2007 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Cochrane Injuries Group methods used in reviews.
We searched the Cochrane Injuries Group trials register,
the Cochrane Controlled Trials Register (2002 Issue 3),
MEDLINE (1966-2002/07), and EMBASE (1974-2002 August
week 1). Bibliographies of trials retrieved were searched, and
drug companies manufacturing colloids were contacted for
information. The search was last updated in September 2002.
Search strategies for each database are given below.
Cochrane Injuries Group Trials Register:
#1 albumin* or hypoalbumin* or plasma* or volume* or starch*
or dextran* or gelofus* or haemacc* or hemacc* or colloid*.
Cochrane Controlled Trials Register (CD, 2002 issue 3):
#1 explode “Albumins” / all SUBHEADINGS
#2 explode “Plasma” / all SUBHEADINGS
#3 explode “Plasma-Substitutes” / all SUBHEADINGS
#4 (volume next replac*) or (human next albumin*)
#5 (frozen next plasma) or (fresh next plasma)
#6 plasma next protein*
#7 (low next albumin*) or hypoalbumin*
#8 starch or dextran* or gelofus* or haemacc* or hemacc*
#9 colloid or colloids
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9.
MEDLINE (Silverplatter, 1966-2002/07):
#1 explode “Albumins” / all SUBHEADINGS
#2 explode “Plasma” / all SUBHEADINGS
#3 explode “Plasma-Substitutes” / all SUBHEADINGS
#4 (volume next replac*) or (human next albumin*)
#5 (frozen next plasma) or (fresh next plasma)
#6 plasma next protein*
#7 (low next albumin*) or hypoalbumin*
#8 starch or dextran* or gelofus* or haemacc* or hemacc*
#9 colloid or colloids
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 #10 and (optimally sensitive MEDLINE search strategy for
identifying randomised controlled trials) (Clarke 2001).
EMBASE (Ovid, 1974-2002 Aug week 1):
#1 exp ALBUMIN/
#2 exp PLASMA/
#3 exp Plasma Substitute/
#4 volume adj replac$
#5 human adj albumin$
#6 (frozen adj plasma) or (fresh adj plasma)
#7 plasma adj protein$
#8 hypoalbumin$ or (low adj albumin)
#9 starch or dextran$ or gelofus$ or haemacc$ or hemacc$
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 Randomized Controlled Trial/ (25290)
#12 randomi$ or double blind$ or single blind$
#13 #11 or #12
#14 #10 and #13.
National Research Register (CD, 2002 issue 3):
As MEDLINE.
Trials were also identified using searches done for an earlier
review of colloids vs crystalloids (Schierhout 2000), which
included BIDS Index to Scientific and Technical Proceedings,
drawing on the handsearching of 29 international journals
and the proceedings of several international meetings on fluid
resuscitation, and checking the reference lists of the trials found.
To identify unpublished trials we searched the UK National
Research Register, the register of the Medical Editors’ Trial
Amnesty, on the Cochrane Library, and we contacted the UK
Medicines Control Agency. We also contacted the medical
directors of the following companies who all manufacture
colloids: Alpha Therapeutic UK Limited (Albutein), American
Critical Care McGraw (Hespan), Bayer (Plasbumin), Baxter
(Gentran), Bio Products Laboratory (Zenalb), Cambridge
Laboratories (Rheomacrodex), Centeon Limited (Albuminar),
CIS UK Ltd , CP (Lomodex), Common Services Agency,
Consolidated (Gelofusine), DuPont (Hespan) Fresenius
(eloHAES and HAES-Steril), Geistlich Sons Ltd (Hespan and
Pentaspan), Hoechst (Haemaccel),Mallinckrodt Medical GMBH
(Infoson), Nycomed, Oxford Nutrition (Elohes), Pharmacia and
Upjohn Ltd (Rheomacrodex), and Sorin Biomedica Diagnostics
Spa.
There were no language restrictions in any of the searches.
M E T H O D S O F T H E R E V I E W
Trial identification
One reviewer examined the electronic search results for reports
of possibly relevant trials and these reports were then retrieved
in full. Two reviewers (PA and FB) applied the selection criteria
independently to the trial reports, resolving disagreements by
discussion.
Quality assessment
Since there is evidence that the quality of allocation concealment
particularly affects the results of studies (Schulz 1995), two
reviewers scored this quality on the scale used by Schulz (Schulz
1995) as shown below, assigning C to poorest quality and A to
best quality:
A=trials deemed to have taken adequate measures to conceal
allocation (i.e. central randomisation; numbered or coded bottles
or containers; drugs prepared by the pharmacy; serially numbered,
opaque, sealed envelopes; or other description that contained
elements convincing of concealment).
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B=trials in which the authors either did not report an allocation
concealment approach at all or reported an approach that did not
fall into one of the other categories.
C=trials in which concealment was inadequate (such as alternation
or reference to case record numbers or to dates of birth)
Where the method used to conceal allocation was not clearly
reported, the author was contacted, if possible, for clarification.
We then compared the scores allocated and resolved differences
by discussion.
Data extraction
Two reviewers independently extracted information on the
following: method of allocation concealment, number of
randomised patients, type of participants and the interventions.
The outcome data sought were numbers of deaths, volume of
blood transfused, and incidence of adverse or allergic reactions.
The reviewers were not blinded to the authors or journal when
doing this, as the value of this has not been established (Berlin
1997). Results were compared and any differences resolved by
discussion.
Where there was insufficient information in the published report,
we attempted to contact the authors for clarification.
Analysis
The following comparisons were made:
- albumin or PPF vs etherified starch
- albumin or PPF vs modified gelatin
- albumin or PPF vs dextran 70
- modified gelatin vs etherified starch
- modified gelatin vs dextran 70
- etherified starch vs dextran 70.
For each trial the relative risk of death and 95%confidence interval
was calculated, such that a relative risk of more than 1 indicates
a higher risk of death in the first group named. Relative risk was
chosen as a measure, as it is more readily applied to the clinical
situation.
The groups of trials were examined for statistical evidence of
heterogeneity using a chi-square test. If there was no obvious
heterogeneity on visual inspection or statistical testing, pooled
relative risks and 95% confidence intervals were calculated using
a fixed-effects model.
We assessed the skewness of continuous data by checking themean
and standard deviation (if available). If the standard deviation is
more than twice the mean for data with a finite end point (such
as 0 in the case of bleeding), the data are likely to be skewed and
it is inappropriate to apply parametric tests (Altman 1996). This
is because the mean is unlikely to be a good measure of central
tendency. If parametric tests could not be applied, we tabulated
the data.
The effect of excluding trials judged to have inadequate (scoring
C) allocation concealment were examined in a sensitivity analysis.
D E S C R I P T I O N O F S T U D I E S
For more detailed descriptions of individual studies, please see the
table of included studies.
A total of 57 trials met the inclusion criteria, with a total of 3659
participants. The earliest trial was from 1980 and the most recent
from 2001. From the drug companies we contacted, we were sent
information by Hoechst, Baxter Health Care Ltd, Fresenius Ltd,
CIS UK Ltd, and Rhemoacrodex. No new trials were identified
from the information sent to us.
The trials included the following comparisons:
Albumin or PPF vs starch (n=35 trials with 1482 participants in
these groups)
Boldt 1986, Boldt 1996A, Boldt 1996B, Boldt 1996C, Boldt
1993, Boldt 1995, Boldt 1998, Brock 1995, Brutocao 1996,
Claes 1992, Diehl 1982, Falk 1988, Fulachier 1994, Gahr 1981,
Gallagher 1985, Gold 1990, Hausdorfer 1986, Hippala 1995,
Huskisson 1993, Kirklin 1984, London 1989, Munsch 1988,
Munoz 1980, Moggio 1983, Mastroianni 1994, Prien 1990,
Rosencher 1992, Rackow 1983, Rackow 1989, Shatney 1983,
Vogt 1994, Vogt 1996, Vogt 1999, Von Sommoggy 1990, Woit-
tiez 1997.
Albumin or PPF vs dextran (n=5 trials with 390 participants in
these groups):
Hedstrand 1987, Hippala 1995, Karanko 1987, Lisander 1996,
Tollosfrud 1995
Albumin or PPF vs gelatin (n=13 trials with 997 participants in
these groups):
Boldt 1986, Du Gres 1989, Huskisson 1993, Karanko 1987,
Stockwell 1992, Stoddart 1996, Tollosfrud 1995, Wahba 1996.
Starch vs gelatin (n=15 trials with 848 participants in these
groups):
Allison 1999, Asfar 2000, Beards 1994, Berard 1995, Beyer 1997,
Boldt 1986, Boldt 2000, Boldt 2001, Carli 2000, Dytkowska,
Haisch 2001a, Haisch 2001b, Huskisson 1993, Huttner 2000,
Schortgen 2001.
Starch vs dextran (n=1 trial with 30 participants in these groups):
Hippala 1995.
Dextran vs gelatin (n=2 trial with 42 participants in these groups):
Karanko 1987, Tollosfrud 1995.
The trials included patients with hypovolaemia, sepsis, trauma,
and patients who had undergone surgery.
The trials tended to report surrogate outcomes such as hemody-
namic variables. Data on death were obtainable from only 31 of
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the trials. Information on the amount of blood transfused was
available in 31 of the trials. However this was reported in a variety
of different ways that made combining the data in a meta-analysis
unfeasible.
Inclusion and exclusion criteria varied, but many of the studies
excluded patients with previous adverse reactions to colloids, clot-
ting problems, or renal disease.
M E T H O D O L O G I C A L Q U A L I T Y
Using predefined criteria (Schulz 1995) the quality of allocation
concealment was judged to be adequate in 20 trials, unclear in
29 trials and inadequate in eight trials. Where the method of
allocation concealment was unclear, we attempted to contact all
of the trialists and we obtained information from 11 of them.
However, due to the lack of reported information on the process
of randomisation and allocation concealment, we were unable to
properly assess the quality of the majority of the trials. Ten trials
mentioned blinding. In four of these those giving the treatment
were blinded, in four those giving post-operative care and were
blinded and in the other two trials the outcome assessors were
blinded.
R E S U L T S
Of the 57 trials identified 24 reportedmortality data. Information
on death was obtained from a further 12 trials by contact with the
authors. We therefore had data on death from 36 trials.
Albumin or PPF vs starch:
Twenty trials (1029 participants) reported mortality data. The
pooled relative risk was 1.17 (95% CI 0.91-1.50).
Albumin or PPF vs gelatin:
Four trials (542 participants) reported mortality but only one of
those trials had any deaths. The relative risk was 0.99 (95% CI
0.69-1.42).
Albumin or PPF vs dextran:
Three trials reported mortality and were included in the meta-
analysis. There were no deaths so relative risk was not estimable.
Gelatin vs starch:
Eleven trials (945 participants) reported mortality and the pooled
relative risk was 1.00 (95% CI 0.78-1.28).
Gelatin vs dextran 70
There were two trials which reported mortality. There were no
deaths so the relative risk was not estimable.
Hydroxyethyl starch vs dextran 70:
No trials reported mortality.
Thirty-five trials recorded the amount of blood transfused. As the
data was reported in various ways, often lacking a measure of
variation, and was also skewed we did not attempt a quantitative
synthesis. This data can be seen in the “other data” table. Fifteen
trials reported the incidence of adverse or allergic reactions or
anaphylactic shock: all reported that there were no such incidents.
The effect of excluding trials judged to have inadequate (scoring
C) allocation concealment was examined in a sub-group analysis.
This made no significant difference to the results.
D I S C U S S I O N
Despite finding 57 trials we cannot make any conclusions about
the relative effectiveness of different colloid solutions. A previous
review suggested that albumin may increase mortality in critically
ill patients (CIGAR 2000), but there are too few data available
to show in direct comparisons whether the synthetic alternatives
are safer. The confidence intervals are wide and do not exclude
clinically significant differences between colloids.
Mortality was selected as the main outcome measure in this sys-
tematic review for several reasons. In the context of critical illness,
death or survival is a clinically relevant outcome that is of imme-
diate importance to patients, and data on death are reported in
many of the studies. Furthermore, one might expect that mor-
tality data would be less prone to measurement error or biased
reporting than would data on pathophysiological outcomes. The
use of a pathophysiological end point as a surrogate for an ad-
verse outcome assumes a direct relationship between the two, an
assumption that may sometimes be inappropriate. Finally, when
trials collect data on a number of physiological end-points, there
is the potential for bias due to the selective publication of end-
points showing striking treatment effects.
There was wide variation in the participants, intervention regi-
mens, and the length of follow-up. The length of follow-up is not
reported in many of the studies. Where it is reported it ranges
from a matter of hours to months, which may explain a lot of
the heterogeneity in overall event rates. The effect of these factors
was not examined in a sensitivity analysis, as there was felt to be
insufficient data to justify examining subgroups.
Many of the trials were small, and some had been done some time
ago. Although older trialswill not necessarily be of poorer quality, it
may be that treatment protocols have subsequently alteredmaking
these trials less relevant to current clinical practice.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Previous reviews have failed to show any benefit of colloids over
crystalloids for volume replacement (Schierhout 2000) and sug-
gested that albumin solution may increase mortality in critically
ill patients (CIGAR 2000).
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This review does not provide any evidence that one colloid is safer
than another, but does not rule out clinically significant differ-
ences.
Implications for research
Trials of fluid therapy need to be larger in order to exclude clin-
ically significant differences between colloids in patient relevant
outcomes. However, trials should probably first address the ques-
tion of whether colloids are any more effective than crystalloid
solutions.
Use of surrogate outcomes, such as physiological measurements
should be discouraged unless there is a strong relationship with
outcomes of interest to patients and relatives.
F E E D B A C K
Colloid solutions for fluid resuscitation
Summary
1. Please explain, in the ’what’s new’ section, in what respects this
update differs from the previous version.
2. The drug companies listed in the acknowledgments are not in
alphabetic order: please do so or explain the reason for the order
shown (e.g. in order of helpfulness).
3. Fresenius is misspelt
4. In the references to included trials, please use an asterisk to
identify those trials which are the main publication where there
are more than one article referring to a trial.
Author’s reply
1. The review has been marked as an update by mistake. As of
September 1999 no substantial updates have been made.
2. The drug companies have been re-ordered alphabetically.
3. The spelling of Fresenius is corrected.
4. The primary reference has been marked with an asterisk.
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T A B L E S
Characteristics of included studies
Study Allison 1999
Methods Randomised controlled trial. Randomisation was based on date of admission (on even dates patients received
HES)
Analysis not intention to treat
Participants 45 patients with blunt trauma who required colloid infusion. Patients were excluded if they were less than
12yrs old, did not require admission to the ITU, died within 24 hours, were pregnant or in renal failure.
8 gelatine and 6 HES patients excluded after randomisation.
Interventions 1) HES (200/0.45 Pentaspan) n=24.
2) Gelatine (gelofusine) n=21
After 24 hours, colloid administration was at the discretion of the clinician.
Outcomes Glasgow coma score,
volumes of blood and platelets infused,
haematological parameters.
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Notes Data were collected until the patient left the ITU or for a maximun of 5 days. Main outcome of interest was
capillary leak.
Allocation concealment C – Inadequate
Study Asfar 2000
Methods Randomised unblinded controlled trial. Allocation using sequentially numbered sealed opaque envelopes
(information obtained on contact with the author).
Participants 34 septic, hypovolaemic, ventilated and hemodynamically controlled patients.
Inclusion criteria: patients aged over 16yr, systolic arterial pressure higher than 90mmHg and hypovolemia
defined by PAOP of 12mmHg or less.
Patients with an overt hemodynamic, ventilatory or acid base status instability were excluded. Sepsis was
identified by either positive bacterial blood cultures, bronchoalveolar lavage or clinical evidence of infection.
Interventions 1) 6% HES (n=16).
2) 4% Modified fluid gelatin (MFG) (n=18).
Outcomes Haemodynamic and tonometric parameters.
Death.
Notes Follow-up was for one hour. Two patients in the HES grp were excluded because they experienced haemo-
dynamic instability. The final analysis was made on remaining 16 patients.
Allocation concealment A – Adequate
Study Beards 1994
Methods Randomised controlled trial (allocation by alternation).
Information on allocation concealment was obtained on contact with the author.
Participants 28 patients with hypovolaemia, mechanically ventilated for concurrent acute respiratory failure. Patients
fulfilled the following inclusion criteria: age >16 yrs, bodyweight between 50 and 85kg, mean arterial pressure
<80mmHg (or 30mmHg less than previously recorded); pulmonary artery occlusion pressure <10mmHg
with oliguria (i.e urine output <15 ml/hr).
Interventions 1) Rapid infusion of 500ml modified fluid gelatin (n=15).
2) Rapid infusion of 500ml hetastarch (n=13).
Outcomes Haemodynamic variables were measured for 30 minutes.
Oxygen variables were measured for 30 minutes.
Deaths in hospital reported.
Notes Patients were followed up to discharge from hospital.
Allocation concealment C – Inadequate
Study Berard 1995
Methods Randomised controlled trial. A set of 200 tickets (type 1) and another set of 200 tickets (type 2) were mixed
in a box. One ticket was drawn at random for each patient. Information on method of randomisation was
obtained on contact with the author. Blinding not mentioned.
Participants 319 patients in a resuscitation service receiving medical (gastrointestinal haemorrhage) and surgical cases.
Patients were excluded if they had had a prior allergic reaction.
Interventions 1) Gelatin (n=153).
2) HES (n=146)
The prescribers chose the quantity of colloid, guided by normal practice.
Outcomes Death.
Amount of colloid and red blood cells given.
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Cost.
Notes 20 patients lost to follow up, no explanation given. Follow up to discharge.
Allocation concealment C – Inadequate
Study Beyer 1997
Methods Randomised controlled trial.
Allocation was by a list of random numbers read by someone not entering patients into the trial (closed list).
Information on method of allocation concealment was obtained by contact with the author. No blinding.
Participants 48 patients undergoing major elective hip surgery with an expected blood loss of >1000 ml. Exclusion criteria
were haemoglobin concentration < or equal to 11g/dl, heart failure and coronary artery disease, myocardial
infarctionwithin the past 6months, hypertension (>180mmHg systolic), impaired renal function, pregnancy,
known hypersensitivity to HES or gelatin, patient taking drugs that may specifically affect blood viscosity,
diuresis or clotting.
Interventions 1) 3% modified fluid gelatin (n=22).
2) 6% HES (n=19)
Both groups also given Ringer’s lactate. Fluids administered according to haemodynamic and clinical param-
eters.
Outcomes Haemodynamic variables.
Packed cell volume, haemoglobin, clotting times.
Incidence of allergic reactions.
Information on death was obtained by contact with the author.
Notes Seven patients were lost to follow up but only 5 were accounted for.
Allocation concealment A – Adequate
Study Boldt 1986
Methods Randomised controlled trial, using sealed opaque envelopes.
Information on allocation concealment was obtained on contact with the authors.
Blinding not mentioned.
Loss to follow up not mentioned.
Participants 55 patients undergoing elective aorto-coronary bypass surgery.
Exclusion criteria were ejection fraction < 50% and LVEDP >15 mmHg.
Interventions 1) 500ml 20% human albumin solution (n=15)
2) 500ml 3% HES (n=13)
3) 500ml 3.5% gelatine (n= 14)
4) no colloid (n=13)
Outcomes Haemodynamic variables were measured.
Incidence of anaphalactic shock measured.
Blood transfused.
Notes Follow-up until discharge from intensive care.
Allocation concealment B – Unclear
Study Boldt 1993 A
Methods Randomised controlled trial. Method of allocation concealment not described in published report. Authors
were contacted and confirmed the use of sequentially numbered sealed opaque envelopes.
Participants 75 men undergoing elective aortocoronary bypass grafting, who had a pulmonary capillary wedge pressure
of less than 5mmHg after induction of anaesthesia.
Interventions 1) Albumin 5%. (n=15)
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2) 6% HES, HMW (n=15)
3) 6% HES, LMW (n=15)
4) Gelatin 3.5% (n=15)
5) No additional volume.
Outcomes Deaths not reported. Authors were contacted and confirmed that there were no deaths in the albumin nor
the control group.
Notes Follow-up 1 day.
Allocation concealment A – Adequate
Study Boldt 1995
Methods Randomised controlled trial. Randomisation was by the use of sequentially numbered sealed opaque en-
velopes. Information on allocation concealment was obtained on contact with the author. Blinding of out-
come assessors not mentioned.
Participants 30 consecutive trauma patients (injury severity score >15) and 30 consecutive septic patients who under-
went major surgery. Exclusions: patients suffering from renal failure requiring haemofiltration, severe liver
dysfunction or coagulation abnormalaties in their history were excluded as were patients who were receiving
aspirin or other cyclooxygenase inhibitors.
Interventions 1) 10% HES, LMW (n=15 trauma pts and 15 sepsis patients)
2) 20% human albumin (n=15 trauma pts and 15 sepsis pts).
Fluid was given to maintain CVP and PCWP between 12 and 16mmHg.
Outcomes Haemodynamic parameters.
Deaths
Notes Length of follow-up was 5 days.
Deaths were reported within the study period and later (time not specified).
Allocation concealment A – Adequate
Study Boldt 1996 A
Methods Randomised controlled trial, allocation by sequentially numbered sealed opaque envelopes.
Outcome assessors blinded to treatment.
Participants 30 trauma patients and 30 patients suffering from sepsis secondary to major general surgery. Exclusions were
patients with renal impairment, liver insufficinecy, disseminated intravascular coagulation or septic shock.
Interventions 1) 10% HES (n=30)
2) 20% human albumin solution (n=30)
All patients also received Ringer’s lactate solution.
Volume therapy was given to maintain PCWP between 12 and 18mm Hg.
Outcomes Haemodynamic variables.
Death at 5 days and discharge from intensive care.
Notes
Allocation concealment A – Adequate
Study Boldt 1996 B
Methods Randomised controlled trial. Randomisation was by the use of sequentially numbered sealed opaque en-
velopes. Information on allocation concealment was obtained on contact with the author.
The doctors giving the fluid were blinded to the solution but blinding of outcome assessors not mentioned.
Loss to follow up not mentioned.
Participants 45 consecutive trauma patients transferred to the surgical intensive care unit. Inclusion criteria were an injury
severity score of >15 points.
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All patients were haemodynamically stable before being admitted to the study.
Interventions 1) 10% HES (n=15).
2) 20% human albumin (n=15).
3) unspecified volume therapy regime (n=15).
The allocated solution was given to maintain CVP and or PAWP between 12 and 18mmHg.
Outcomes Death.
Haemodynamic variables.
Circulating adhesion molecules.
Notes Deaths were reported within the study period and later (left ITU).
Allocation concealment A – Adequate
Study Boldt 1996 C
Methods Randomised controlled study. Randomisation was by the use of sequentially numbered sealed opaque en-
velopes. Outcome variables were collected by an investigator who was blinded to the treatment.
Loss to follow up not mentioned.
Participants 56 patients from the surgical intensive care unit. 28 patients with an injury severity score >15 and 28 patients
with sepsis secondary to major surgery. Patients with renal insufficiency, urine output <20ml h, severe liver
dysfunction or disseminated intravascular coagulation were excluded.
Interventions 1) 10% HES, LMW (trauma n=14, sepsis n=14)
2) 20% human albumin. (trauma n=14, sepsis n=14)
Fluid was infused to maintain PCWP at 10-15mmHg.
Outcomes Haemodynamic variables.
Death.
Notes Length of follow up was 5 days.
Deaths were reported within the study period and later (time not specified).
Allocation concealment A – Adequate
Study Boldt 1998
Methods Randomised controlled trial. Sequentially numbered sealed opaque envelopes were used. Information on
allocation concealment was obtained on contact with the authors.
Blinding of outcome assessors not mentioned.
Loss to follow up not mentioned.
Participants 150 traumatised patients (injury severity score >15) and 150 postoperative patients with sepsis. Patients
suffering from renal failure, severe liver insufficiency, or with major coagulation abnormalaties were not
included.
Interventions 1) 10% HES, LMW (n=150).
2) 20% human albumin (n=150). Both for 5 days to maintain the pulmonary wedge pressure between 12
and 15 TORR
Outcomes Death.
Haemodynamic variables.
Organ function.
Coagulation.
Notes Deaths were reported within the study period and after the study period (time not specified).
Allocation concealment A – Adequate
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Study Boldt 2000
Methods Randomised controlled trial. Allocation by sequentially numbered sealed opaque envelopes (information
obtained by contacting the author)
Participants 150 patients undergoing major abdominal surgery
Interventions 1) 6% HES, LMW (n=50).
2) 6% HES, MMW (n=50).
3) 3% modified fluid gelatin (n=50)
To keep MAP more than 70 mm Hg and CVP between 10 and 14 mm Hg.
Volume was given perioperatively until the morning of the first post-op day. For each hour of surgery 500-
800ml of crsytalloids was routinely infused.
Outcomes Death.
Haemodynamic variables,
blood loss,
blood transfused,
cost.
Notes Deaths were reported for the study period (when there were no deaths) and after the study period (when
there was 1 death in the HES 70 grp, 2 deaths in the HES 200 grp and 1 death in the gelatin grp).
The study period lasted until the first day post-op.
Allocation concealment A – Adequate
Study Boldt 2001
Methods Randomised controlled trial. Allocation by a “closed envelope system”.
Volume therapy was done by doctors who did not know the aim of the study.
Participants 75 patients undergoing major abdominal surgery.
Volume was administered to keep the CVP between 8 and 12mmHg.
Interventions 1) 6% HES (n=25).
2) 6% HES (n=25).
3) 4% modified fluid gelatin (n=25)
All groups also received 500ml of ringers lactate for each hour of surgery.
Outcomes Death.
Haemodynamic variables,
blood loss,
blood transfused.
Notes There were no deaths in the study period (until first postoperative day) but afterwards there was one death
in the colloids group and no deaths in the gelatin group.
Allocation concealment A – Adequate
Study Brock 1995
Methods Randomised controlled trial with list of random numbers read by someone entering patients into the trial
(open list). Data on allocation concealment was obtained on contact with the authors.
Participants 21 patients who had undergone cardiac surgery.
Interventions 1) 10% HES. 200/0.5 in 7.2% saline (n=7)
2) 5% human albumin (n=7).
3) 6% hydroxyethylstarch in 0.9% saline (n=7).
Outcomes Hemodynamic variables were collected.
Data on death was obtained on contact with the authors.
Notes
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Allocation concealment C – Inadequate
Study Brutocao 1996
Methods Randomised double-blind controlled trial with pharmacy controlled randomisation. Information on alloca-
tion concealment was obtained on contact with the authors.
Participants Children aged 1 year or more who were undergoing surgical repair of a congenital heart disease. Exclusion
criteria included amrinone therapy, renal disease, coagulopathy or a known bleeding diathesis.
Interventions 1) 5% albumin (n=18).
2) 6% HES (n=20).
Volume expansion was administered as clinically indicated to maintain adequate central venous pressure,
perfusion and urine output. The total amount of colloid therapy was determined by care providers blinded
to the randomisation.
Outcomes Haemodynamic variables.
Coagulation variables.
Information on death was obtained on contact with the authors.
Notes Follow-up was until discharge from hospital.
9 children excluded post randomisation because they did not require colloid.
Allocation concealment A – Adequate
Study Carli 2000
Methods Randomised controlled trial. Each centre had a list and the patients were randomised by the regulatory Dr
of the Institute.
Participants 164 trauma patients. Patients were included if their SBP was less than 100mmHg, associated with signs of
hypoperfusion.
Interventions 1) HES (Hesteril 6%) (n= 85).
2) Gelatin (Plasmion)
(n=79)
Outcomes Glasgow coma score.
Haemodynamic variables
Units of blood transfused
Adverse reaction
Notes There were 13 deaths from heart failure but these patients were excluded from the final analysis.
Allocation concealment B – Unclear
Study Claes 1992
Methods Randomised controlled trial. No information given on method of randomisation.
Blinding not mentioned.
No loss to follow up.
Participants 20 patients undergoing brain tumor surgery and 20 patients undergoing transabdominal hysterectomy.
Exclusion criteria were preexisting coagulopathies; abnormal preoperative coagulation screening tests; intake
of drugs affecting haemostasis within 2 wk preoperatively as well as liver or kidney dysfunction.
Interventions 1000ml of fluid for volume replacement, either as
1) 6% HES (n=19).
2) 5% human albumin solution in 0.9% NaCl (n=21).
Outcomes Haemodynamic variables.
Coagulation variables.
Notes Follow up 48 hrs post-op.
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Allocation concealment B – Unclear
Study Diehl 1982
Methods Randomised controlled trial. Patients were allocated to groups according to their hospital identification
number.
Blinding not mentioned.
No loss to follow up.
Participants 60 Patients undergoing coronary artery bypass.
Interventions 1) 6% HES (n=27)
2) 5% albumin (n=33)
for volume expansion during the first 24 hours postoperatively. Neither hetastarch or albumin was used
intraoperatively or in the pump prime.
Outcomes Death.
Coagulation data.
Haemodynamic variables.
Notes Followup 7 days post-op.
Allocation concealment C – Inadequate
Study Du Gres 1989
Methods Randomised controlled trial. No information given on method of randomisation.
Blinding not mentioned.
No loss to follow up.
Participants 30 patients post cardiac surgery. Patients were included if they were haemodynamically stable, were without
serious ’rhythm’ problems, had amean arterial pressure less than 90mmHg, amean pulmonary artery pressure
less than 20mmHg and a central venous pressure less than 10mmHg. Patients excluded if they needed blood
transfusion, had a hematocrit less than 28% or haemoglobin less than 9g/100ml.
Interventions 1) 4% human albumin (n=15).
2) Haemaccel (n=15).
Outcomes Haemodynamic parameters.
Notes Follow up 4 hours.
Allocation concealment B – Unclear
Study Dytkowska 1998
Methods Randomised controlled trial. No information given on method of allocation concealment
Participants 40 patients post cardiac surgery. Patients were excluded if they had co-existing cardiogenic shock, renal failure
with creatine level over 3.0mg or severe clotting disorders.
Interventions 1) 200/0 HAES 6% (n=20).
2) Gelafundin (n=20)
Colloids were administered to patients with diagnosed symptoms of hypovolaemia, during the first 24 hours
post-op. Infusion rate was adjusted to patients needs but it did not exceed 1000ml/h
Outcomes Haemodynamic parameters.
Biochemical parameters.
Adverse reactions.
Notes Follow up 2 hours.
Allocation concealment B – Unclear
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Study Falk 1988
Methods Randomised controlled trial. No information given on method of randomisation.
Blinding not mentioned.
No loss to follow up.
Participants 12 patients with septic shock. Patients were excluded from the study if the pretreatment PAWP was greater
than 10mmHg.
Interventions 1) 250ml of 5% albumin (n=6).
2) 250ml of 6% HES (n=6).
every 15 minutes until the PAWP was increased to 15mmHg. The test infusion was then continued at 100
mL/hour to maintain PAWP at 15 mm Hg for the next 24 hours.
Outcomes Haemodynamic variables.
Clotting variables.
Notes Follow up 24 hours.
Allocation concealment B – Unclear
Study Fulachier 1994
Methods Randomised controlled trial. No information given on method of randomisation.
Blinding not mentioned.
No loss to follow up.
Participants 16 patients undergoing cardiac surgery (8 were undergoing valve replacement and 8 coronary bypass) Patients
were excluded if they were over 80, under 18 yrs of age, had been included in other studies, had received
colloids in the month preceding surgery, had coagulation abnormalaties or who were undergoing inotropic
treatment.
Interventions 1) 500ml of a 4% solution of human albumin in Ringer’s lactate (n=8)
2) 500ml of hydroxyethylstarch (n=8)
until starting cardiopulmonary bypass.
Outcomes Haemodynamic variables.
Notes Follow up 30 minutes.
Allocation concealment B – Unclear
Study Gahr 1981
Methods Randomised controlled trial. No information given on method of randomisation.
No loss to follow up
Participants 20 patients with hypovolaemia following abdominal surgery for malignoma.
Interventions 1) 500ml HES 450/0.7 (n=10).
2) 500ml human albumin 5% (n=10)
during the first 24 hrs after the operation
Outcomes Haemodynamic parameters
Coagulation data.
Notes Follow up 6 hrs.
Allocation concealment B – Unclear
Study Gallagher 1985
Methods Randomised controlled trial. Author contacted - allocation concealment by computerised system - patient
details were entered before treatment assignment was revealed.
Participants 10 patients after coronary artery bypass graft surgery.
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Exclusions: patients with significant left main coronary artery stenosis, poor left ventricular function or poor
pulmonary function.
Interventions 1) 5% albumin (n=5).
2) 6% HES (n=5).
Outcomes Data on deaths from author.
Haemodynamic data.
Notes Follow up 1 day.
Allocation concealment A – Adequate
Study Gold 1990
Methods Randomised controlled trial. Randomisation was done by alternation. Colloid solution was blinded by
covering with foil. Information on allocation concealment was obtained by contact with the author.
No loss to follow up.
Participants 40 Surgical patients undergoing abdominal aortic aneurysm surgery.
Interventions 1) 1g/kg of albumin 5% solution (n=20).
2) 1g/kg or hetastarch 6% solution (n=20).
Outcomes Haemodynamic and coagulation variables were measured. Data on death was obtained on contact with the
author.
Notes Length of follow up not specified.
Allocation concealment C – Inadequate
Study Haisch 2001a
Methods Randomised controlled trial. No information given on method of allocation concealment.
Patient management by doctors who were blided to the grouping.
Participants 42 patients undergoing cardiac surgery. Patients were excluded if they had: an MI within previous 3 months,
renal insufficiency, liver insufficiency, non controlled diabetes mellitus, preoperative coagulation abnormal-
ities or patients treated with heparin or cyclooxygenase inhibitors within last 7 days.
Interventions 1) Gelatin (n=21).
2) HES (n=21).
Outcomes Deaths.
Use of blood products.
Notes Follow up until first postoperative day.
Allocation concealment B – Unclear
Study Haisch 2001b
Methods Randomised controlled trial using computer generated random numbers. No information given on allocation
concealment.
Participants 42 patients undergoing major abdominal surgery for malignancies.
Patientswere excluded if they had cardiac insufficiency, renal insufficiency, altered liver function, pre-operative
anemia, pre-operative coagulation abnormalities or if they had had cycloxygenase inhibitors.
Interventions 1) HES (n=21).
2) Gelatin (n=21)
until the morning of the first post-operative day.
Outcomes Death.
Use of allogenic blood products.
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Coagulation variables.
Notes Follow up until first postoperative day.
Allocation concealment B – Unclear
Study Hausdorfer 1986
Methods Randomised controlled trial. No information given on method of randomisation.
Participants 30 children undergoing major surgery. During about 3 hours of surgery, the patients lost up to 15% of blood
volume.
Interventions 1) Human albumin 5% (n=15).
2) HES 6% (n=15) with 14ml/kg body weight each, respectively.
Outcomes Haemodynamic variables.
Notes Follow up 24 hours post-op.
Allocation concealment B – Unclear
Study Hedstrand 1987
Methods Randomised controlled trial. no information given on method of randomisation.
Post-op care staff were blinded.
No loss to follow up.
Participants 275 patients underdoing major surgery. Patients were excluded if they if they were known to have decreased
serum albumin levels or expected to sustain plasma loss, or had pronounced cardiovascular disease.
Interventions 1) PPF (n=142).
2) Dextran (n=133.
Outcomes Volume transfused.
Complication rates.
Serum albumin
Deaths
Notes Follow up one month.
Allocation concealment B – Unclear
Study Hiippala 1995
Methods Randomised controlled trial. No information given on method of randomisation.
Blinding not mentioned.
3 patients lost to follow up (explanation given).
Participants 60 patients undergoing major abdominal or urological surgery. Patients who had used platelet inhibiting
drugs or had a diagnosed haemostatic defect were excluded.
Interventions 1) 3% dextrose (n=15).
2) 4% HES (n=15).
3) 6% HES (n=15).
4) 5% albumin (n=15).
Outcomes Haemodynamic variables.
Clotting variables.
Blood loss.
Notes Follow up 3 days post-op.
Allocation concealment B – Unclear
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Study Huskisson 1993
Methods Randomised controlled trial. No information given on method of randomisation.
Participants 27 children returning to the intensive care unit following hypothermic open heart surgery.
Interventions 1) Albumin.
2) Gelatin.
3) Hetastarch.
Outcomes Haemodynamic variables.
Notes
Allocation concealment B – Unclear
Study Huttner 2000
Methods Randomised controlled trial. Allocation concealment using ’blind envelopes’. Anaesthetists responsible for
patients management were blinded to the grouping.
Participants 60 patients undergoing major abdominal surgery. Patients were excluded if they had any of the following:
cardiac insufficiency, renal insufficiency, liver dysfunction, pre-operative anaemia or coagulation abnormali-
ties, or were on cyclooxygenase inhibitors or non steroidal therapy.
Interventions 1) 4% Gelatin (n=20).
2) 6% LMW HES (n=20).
3) 6% MMW HES (n=20).
Outcomes Haemodynamic variables.
Clotting. variables.
Death
Notes Follow up until first postoperative day.
Allocation concealment A – Adequate
Study Karanko 1987
Methods Randomised controlled trial. Patients were randomised in blocks of four. Paper was put into a hat and taken
out by an independant person. Information on method of randomisation was obtained on contact with the
author.
Blinding not mentioned.
No loss to follow up.
Participants 48 patients who had undergone coronary bypass surgery 20 hrs earlier.
Interventions 1) 4% PPF (n=15).
2) 6% dextran-70 (n=10).
3) 5.5% Oxypolygelatin (n=12),
4) Control group (n=11). This group were not selected randomly.
Outcomes Hemodynamic variables.
Data on death was obtained on contact with the author.
Notes Follow up 28 hrs. No deaths within the study period.
Allocation concealment C – Inadequate
Study Kirklin 1984
Methods Randomised controlled trial. No information given on method of randomisation.
Blinding not mentioned.
No loss to follow up.
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Participants 30 patients undergoing coronary artery operations. Patients were excluded if they had undergone previous
cardiac operations, if they had severe coagulopathies, anemia or chronic renal failure.
Interventions 1) 6% HES (n=15).
2) 5% albumin (n=15).
Both fluids infused over 24 hours to maintain left artial pressure between 6 and 12mmHg and cardiac index
greater than 2.0L/min/m2
Outcomes Haemodynamic and coagulation variables and data on death and adverse reactions were collected.
Notes Follow up until discharge from Intensive care.
34 patients were originally included in the trial but data from 4 of themwas not included in the final analysis.
Allocation concealment B – Unclear
Study Lisander 1996
Methods Randomised controlled trial. Randomisation using sequentially numbered sealed opaque envelopes. Infor-
mation on allocation concealment was obtained on contact with the author.
No loss to follow up.
Blinding not mentioned.
Participants 40 patients undergoing revision hip arthroplasty.
Interventions 1) albumin 40g/L (n=20).
2) dextran 70 60g/L (n=20).
Patients all received enoxaparin 40mg daily.
Outcomes External blood loss.
Red cell balance.
Packed cell volume.
Notes Follow up until discharge from hospital. Data on death was obtained on contact with the author.
Allocation concealment A – Adequate
Study London 1989
Methods Randomised controlled trial. No information given on method of randomisation.
Blinding not mentioned.
No loss to follow up.
Participants 93 male cardiac surgical patients. Patients were excluded from the study if they had a significant coagulopathy
or were anaemic (haematocrit value <30%).
Interventions 1) 10%. pentastarch in 0.9% saline (n=50).
2) 5% human albumin in 0.9% saline (n=44)
to provide volume expansion during the first 24 hours after cardiac operations.
Outcomes Haemodynamic variables.
Coagulation variables.
Death.
Length of stay.
Notes One patient was treated twice with an 8-month interval. Follow up until discharge from hospital.
Allocation concealment B – Unclear
Study Mastroianni 1994
Methods Randomised controlled trial. No information given on method of randomisation.
Blinding not mentioned.
Participants 34 patients undergoing open heart surgery were enrolled.
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Interventions 1) 10% pentastarch. (n=12).
2) 5% albumin (n=17).
Outcomes Haemodynamics variables.
Clotting variables.
Pulmonary oedema.
Death.
Notes Follow up 7 days.
Four patients in the pentastarch group, and one patient in the albumin group were excluded after randomi-
sation.
Allocation concealment B – Unclear
Study Moggio 1983
Methods Patients were randomised according to the last digit of their hospital identification numbers.
No loss to follow up.
Blinding not mentioned.
Participants 47 postoperative open heart surgery patients. Operations performed included coronary revascularisation,
valve operations, and combined coronary and valve procedures. Patients with pre existing hepatic or renal
disease were not eligible for the study.
Interventions 1) 5% albumin in 0.9% NaCl (n=23).
2) 6% HES in 0.9% NaCl (n=24).
Outcomes Haemodynamic variables.
Clotting variables.
Notes Follow up not specified.
Allocation concealment C – Inadequate
Study Munoz 1980
Methods Randomised controlled trial. No information given on method of randomisation.
Blinding not mentioned.
No mention of loss to follow up.
Participants 14 patients with shock due to haemorrhage or sepsis.
Interventions Patients received either
1) HES (hespan)
2) 5% albumin
Number in each group not reported.
Outcomes Haemodynamic variables.
Notes Follow up 4 hrs post infusion.
Allocation concealment B – Unclear
Study Munsch 1988
Methods Randomised controlled trial. No information given on method of randomisation.
Blinding not mentioned.
No loss to follow up.
Participants 40 consecutive patients undergoing elective coronary artery bypass graft surgery.
Interventions 1) HES 6% (n=20) or
2) PPF (n=20)
as their postoperative volume expander.
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Outcomes Haemodynamic variables.
Clotting variables.
Death.
Adverse reactions.
Notes Follow up 7 days post -op.
Allocation concealment B – Unclear
Study Prien 1990
Methods Randomised controlled trial. Method of allocation concealment unknown.
Blinding not mentioned.
Loss to follow up not mentioned.
Participants 18 patients undergoing modifiedWhipple’s operation (hemipancreato-duodenectomy). Patients were eligible
for the study if there was an absence of major organ dysfunction and serum protein, sodium, glucose, blood
urea nitrogen, haematocrit, aPTT and PT times, and platelet times were within normal limits. Specific
exclusion criteria included compensated myocardial insufficiency, chronic hypertension, chronic obstructive
airways disease and insulin-dependent diabetes mellitus.
Interventions 1) 10% HES (n=6).
2) 20% human albumin (n=6).
3) Ringer’s lactate (n=6)
All given as a volume replacement solution, which was given to maintain central venous pressure at the pre-
operative level.
Outcomes Haemodynamic variables.
Clotting variables.
Data on death was obtained on contact with the author.
Notes Follow up not specified.
Study was intra-operative.
Allocation concealment B – Unclear
Study Rackow 1983
Methods Randomised controlled trial, method of allocation concealment not mentioned.
Blinding not mentioned.
Participants 18 patients with hypovolemic and septic shock. Patients were excluded if they were less than 18 yrs of age,
considered to be in a terminal state, or had a significant coagulopathy.
Interventions 1) albumin (n=9).
2) HES (n=9).
Patients received 250ml of the treatment fluid every 15 min as a fluid challenge. The fluid challenge ended
when the WP equalled 15
mmHg. Thereafter the treatment fluid was given in sufficient quantities to maintain the WP at 15mmHg
for the next 24h, at which point the study was completed.
Outcomes Death.
Haemodynamic variables.
Respiratory variables.
Notes Deaths given for study period and for length of hospital stay. Survival until discharge was used for the
mortality data for this review.
Allocation concealment B – Unclear
Study Rackow 1989
Methods Randomised controlled trial. Method of allocation concealment was not recorded.
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Characteristics of included studies (Continued )
No loss to follow up.
Blinding not mentioned.
Participants 20 patients with severe sepsis and systemic hypoperfusion. Patients were excluded from the study if they were
<21 yrs of age, pregnant, considered to be terminal, or they manifested spontaneous bleeding.
Interventions 1) 5% albumin (n=10)
2) 10% hydroxyethyl starch (pentastarch) (n=10)
Each group received 250ml of the treatment fluid every 15 mins until either theWP was > or equal to 15mm
Hg or a maximum volume of 2000ml of study colloid was infused.
Outcomes Haemodynamic variables
Clotting variables
Deaths
Allergic reactions.
Notes Length of follow up unspecified.
Allocation concealment B – Unclear
Study Rosencher 1992
Methods Randomised controlled trial. Randomisation was done using sequentially numbered, sealed, opaque en-
velopes. Information on allocation concealment was obtained on contact with the author.
No mention of blinding.
Loss to follow up not mentioned.
Participants 16 patients undergoing total hip replacement.
Interventions 1) 4% albumin
2) elohes (LMW hydroxyethyl starch).
Numbers in each group not reported.
Outcomes Bleeding.
Clotting variables.
Notes Data on death was obtained on contact with the author.
Follow up for 5 days post op.
Allocation concealment A – Adequate
Study Schortgen 2001
Methods Randomised controlled trial. Allocation was by sealed opaque envelopes serially numbered and used in
sequence.
Participants 129 patients with severe sepsis or septic shock over 18 years of age. Patients were excluded if they were
pregnant, had a history of allergy toHES or gelatin, had severe acute or chronic renal dysfunction or previous
administration of HES or mannitol.
Interventions 1) 6% hydroxyethylstarch (n=65).
2) 3% fluid-modified gelatin (n= 64).
Outcomes Death.
Length of stay in ITU.
Acute renal failure.
Notes Follow up while in ITU.
Data on death. was obtained on contact with the author.
Allocation concealment A – Adequate
Study Shatney 1983
Methods Controlled clinical trial. Patients were assigned to groups in an alternating fashion.
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Characteristics of included studies (Continued )
No loss to follow up.
No mention of blinding.
Participants 32 patients with multisystem trauma and/or haemorrhagic shock. Patients with cardiac arrest on hospital
admission or during the first half hour after admission were excluded from the study.
Interventions 1) Plasma protein fraction (PPF) 5% solution (n=16),
2) Hetastarch 6% (n=16).
Study patients continued to receive the assigned colloid solution for the first 8 days whenever colloid was
thought necessary.
Outcomes Hepatic, pulmonary and renal function.
Clotting variables
Volume of fluids infused.
Deaths
Notes Follow up 8 days.
Allocation concealment C – Inadequate
Study Stockwell 1992
Methods Randomised controlled trial. No information given on method of randomisation.
No loss to follow up.
Blinding not mentioned.
Participants 475 patients admitted to the intensive care unit. Patients were excluded from the study if they were under
18 yrs or if admitted for cardiac monitoring or cardiac thrombolytic therapy.
Interventions 1) 4.5% albumin (n=226).
2) A synthetic colloid polygeline (Haemaccel) (n=249)
for intravenous volume replacement.
Outcomes Death.
Length of stay in ITU.
Incidence of renal failure.
Pulmonary oedema.
Notes Follow up until discharge from ITU.
Allocation concealment B – Unclear
Study Stoddart 1996
Methods Randomised blinded trial. Sequentially numbered sealed opaque envelopes were used. Information on allo-
cation concealment was obtained on contact with the author.
Anaesthetist unaware of intervention.
No loss to follow up.
Participants 30 neonates undergoing major surgery. They were excluded if the body weight was less than 2kg or more than
5kg, the preoperative haemoglobin was less than 14g/d1, they had previously received blood or colloid, or
they had suspectedmajor cardiac, renal, metabolic or chromosomal abnormalities. Neonates were withdrawn
from the study if either blood or more than 40ml/kg of colloid was required either during or within the first
24hr after surgery.
Interventions 1) Human albumin solution 4.5% (n=15).
2) Haemaccel (n=15).
Outcomes Haemodynamic variables.
Plasma albumin.
Haemoglobin.
Notes Follow up 24 hrs post op.
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Characteristics of included studies (Continued )
Data on deaths not collected.
Allocation concealment A – Adequate
Study Tollofsrud 1995
Methods Randomised controlled trial. Allocation concealment was by the use of sequentially numbered sealed opaque
envelopes. Information on allocation concealment was obtained on contact with the authors.
No loss to follow up.
Blinding not mentioned.
Participants 40 Patients undergoing elective coronary artery bypass surgery. Patients with left ventricular ejection fraction
less than 40%, valvular heart disease, ventricular aneurysm, arrhythmia, diabetes mellitus, renal failure or
lung disease were excluded.
Interventions 1) Polygeline (Haemaccel) (n=10)
2) Dextran 70 (n=10)
3) Albumin 40 (n=10)
4) Ringers Lactate (n=10).
Outcomes Death.
Haemodynamic variables.
Respiratory data.
Cost of fluid regimens.
Notes Length of follow up 48 hours during and after surgery.
Allocation concealment A – Adequate
Study Vogt 1994
Methods Randomised controlled trial. No information given on method of randomisation.
Participants 40 patients undergoing major surgery. Exclusion criteria included anaemia, renal, liver and coagulation
disorders.
Interventions 1) 5% human albumin (n=20).
2) 6% hydroxyethyl starch (n=20).
Outcomes Haemodynamic variables.
Coagulation.
Haematological parameters.
Blood loss and blood intake.
Notes
Allocation concealment B – Unclear
Study Vogt 1996
Methods The patients were divided into two groups using random numbers.
Blinding not mentioned.
No loss to follow up.
Participants 41 patients undergoing total hip arthroplasty during the perioperative period. Exclusion criteria were weight
<60 kg, age <18 yrs, ASA grade>III, haematocrit <34% or >44%, history of coagulopathies or a Quick’s
prothrombin test of < 75%, partial thromboplastin time (PTT) > 45s, platelet count < 100,000/mm3,
impaired liver function and renal failure.
Interventions 1) 6% HES (n=20).
2) 5% human albumin (n=21).
Outcomes Haemodynamic.
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Characteristics of included studies (Continued )
Clotting variables.
Notes Length of follow up was 6 hrs post-op.
Allocation concealment B – Unclear
Study Vogt 1999
Methods Randomised controlled trial. No information given on method of randomisation.
Participants 50 patients undergoing radical prostatectomy or cystectomy with bladder replacement.
Exclusion criteria were: weight less than 60kg,
age less than 21 yrs, ASA 1 or 2,
haemoglobin less than 12g/dl,
history of clotting disorders,
liver function disorders,
advanced renal insufficiency or hypoproteinaemnia.
Interventions 1) 5% human albumin.
2) 6% HES 200/0.5.
Outcomes Haemodynamic parameters.
Blood loss.
Notes Follow up was for 3 days.
Allocation concealment B – Unclear
Study Wahba 1996
Methods Randomised controlled trial. Computerised systemwas used for randomisation.Data onmethod of allocation
concealment was obtained on contact with the author.
Blinding not mentioned.
Loss to follow up not mentioned.
Participants 20 patients who had had coronary artery bypass grafting. Patients with abnormal left-ventricular function as
judged from cine-angiography were excluded as were patients on anticoagulants less than 10 days before the
operation.
Interventions 1) 5% albumin (n=10)
2) Haemaccel (n=10)
Number of patients in each group not specified.
Outcomes Haemodynamic variables.
Data on death was obtained on contact with the author.
Notes Length of follow up was 2 weeks.
Allocation concealment A – Adequate
Study Watkins 1990
Methods Randomised controlled trial. No information given on method of randomisation.
Participants 12 patients undergoing major surgery.
Interventions 1) LMW polystarch or
2) Polygelatine (Haemaccel)
for postoperative volume replacement.
Outcomes Death and incidence of adverse reactions are reported. Detailed complement assay done.
Notes Follow up was for 24 hours after the infusion.
Allocation concealment B – Unclear
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Study Woittiez 1997
Methods Randomised controlled trial.
Allocation concealment by sequentially numbered sealed opaque envelopes.
Participants 60 patients who had developed hypoalbuminaemia (<20g/l) after major surgery.
2 patients died after randomisation and before treatment started. These were excluded from the analysis.
Interventions 1) saline (500ml/24 hr) (n=16).
2) albumin 20% (300 ml/24h) (n=15).
3) HES 10% (500ml/24h) for 3 days (n=27).
Aim was to restore colloid osmotic pressure.
Outcomes Changes in fluid balance, serum albumin, COP and clinical signs of oedema were followed daily.
Data on death supplied by the author.
Notes Length of follow up unspecified.
Allocation concealment A – Adequate
Study von Sommoggy 1990
Methods Randomised controlled trial. No information given on method of randomisation.
No loss to follow up.
Participants 24 patients undergoing infrarenal aortofemoral bifurcation grafting.
Interventions 1) FFP and 5% human albumin (n=13).
2) Hydroxyethyl starch (HES) 200 10% and HES 450 6%. (n=11).
Outcomes Haemodynamic variables.
Clotting variables.
Influence on organ function.
Notes Follow up 6 hrs post-op.
Allocation concealment B – Unclear
CVP = central venous pressure
HES = hydroxyethyl starch
HMW = high molecular weight
LMW = low molecular weight
LVEDP = left ventricular end diastolic pressure
MMW = medium molecular weight
MAP = mean arterial pressure
PAWP = pulmonary artery wedge pressure
PAOP = pulmonary artery occlusion pressure
PCWP = pulmonary capillary wedge pressure
Characteristics of excluded studies
Study Reason for exclusion
Boldt 1993 Pre-bypass volume loading.
Boldt 2000b Compares two starches with each other.
Brehme 1993 Haemodilution.
Bremerich 2000 Compares two different starches (acetyl starch with hydroxyethyl starch).
Charlet 1991 Study compared two different gelatines with each other and not with other colloids.
Christ 1997 Non-randomised trial.
Emery 1992 Trial compares 20% and 4.5% albumin with each other and not with other colloids.
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Characteristics of excluded studies (Continued )
Gan 1999 Compares Hextend (a plasma volume expander based upon 6% hetastarch) with 6% hetastarch in saline (HES).
Hankeln 1990 Haemodilution
Harke 1976 Unable to find out if a randomised controlled trial. Methodology unclear.
Hiippala 1996 Patients were expected to have minimal blood loss
Huet 2000 Compares two starches with each other.
Jovanovic 1997 Does not mention if study was randomised. Unable to contact author for further information.
Korttila 1984 Healthy volunteers and cross over trial.
Langeron 2001 Compares two starches with each other
Puri 1983 There is no mention of a method of randomisation. Just says “Twenty-five patients studied in each group were well
matched”.
Rauch 2000 Compares two starches with each other.
Rehm 2000 Haemodilution.
Strauss 1985 Healthy volunteers.
Waxman 1989 Cross-over study.
A N A L Y S E S
Comparison 01. Albumin or PPF vs Hydroxyethyl Starch
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Death 20 1029 Relative Risk (Fixed) 95% CI 1.17 [0.91, 1.50]
02 Blood/red cells transfused
(skewed or inadequate data)
Other data No numeric data
Comparison 02. Albumin or PPF vs Gelatin
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Death 4 542 Relative Risk (Fixed) 95% CI 0.99 [0.69, 1.42]
02 Blood/red cells transfused
(skewed or inadequate data)
Other data No numeric data
Comparison 03. Albumin or PPF vs Dextran
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Death 3 85 Relative Risk (Fixed) 95% CI Not estimable
02 Blood/red cells transfused
(skewed or inadequate data)
Other data No numeric data
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Comparison 04. Modified Gelatin vs Hydroxyethyl starch
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Death 11 945 Relative Risk (Fixed) 95% CI 1.00 [0.78, 1.28]
02 Blood/red cells transfused
(skewed or inadequate data)
Other data No numeric data
Comparison 05. Modified Gelatin vs Dextran
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Death 2 42 Relative Risk (Fixed) 95% CI Not estimable
02 Blood/red cells transfused
(skewed or inadequate data)
Other data No numeric data
Comparison 06. Hydroxyethyl starch vs Dextran
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Death 0 0 Relative Risk (Fixed) 95% CI Not estimable
02 Blood/red cells transfused
(skewed or inadequate data)
Other data No numeric data
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Analysis 01.01. Comparison 01 Albumin or PPF vs Hydroxyethyl Starch, Outcome 01 Death
Review: Colloid solutions for fluid resuscitation
Comparison: 01 Albumin or PPF vs Hydroxyethyl Starch
Outcome: 01 Death
Study Albumin or PPF Hydroxyethyl starch Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Boldt 1995 6/30 5/30 6.4 1.20 [ 0.41, 3.51 ]
Boldt 1996 A 9/30 7/30 8.9 1.29 [ 0.55, 3.00 ]
Boldt 1996 B 2/15 1/15 1.3 2.00 [ 0.20, 19.78 ]
Boldt 1996 C 10/28 9/28 11.4 1.11 [ 0.53, 2.31 ]
Boldt 1998 39/150 31/150 39.4 1.26 [ 0.83, 1.90 ]
x Brock 1995 0/7 0/14 0.0 Not estimable
x Brutocao 1996 0/18 0/20 0.0 Not estimable
x Diehl 1982 0/33 0/27 0.0 Not estimable
x Gallagher 1985 0/5 0/5 0.0 Not estimable
x Gold 1990 0/20 0/20 0.0 Not estimable
x Kirklin 1984 0/15 0/15 0.0 Not estimable
London 1989 1/44 2/50 2.4 0.57 [ 0.05, 6.05 ]
x Mastroianni 1994 0/18 0/16 0.0 Not estimable
x Munsch 1988 0/20 0/20 0.0 Not estimable
Prien 1990 0/6 1/6 1.9 0.33 [ 0.02, 6.86 ]
Rackow 1983 6/9 5/9 6.4 1.20 [ 0.57, 2.53 ]
Rackow 1989 5/10 5/10 6.4 1.00 [ 0.42, 2.40 ]
x Rosencher 1992 0/16 0/16 0.0 Not estimable
Shatney 1983 3/16 3/16 3.8 1.00 [ 0.24, 4.23 ]
Woittiez 1997 8/15 13/27 11.8 1.11 [ 0.60, 2.05 ]
Total (95% CI) 505 524 100.0 1.17 [ 0.91, 1.50 ]
Total events: 89 (Albumin or PPF), 82 (Hydroxyethyl starch)
Test for heterogeneity chi-square=1.62 df=10 p=1.00 I² =0.0%
Test for overall effect z=1.21 p=0.2
0.1 0.2 0.5 1 2 5 10
Albumin or PPF Hydroxyethyl starch
Analysis 01.02. Comparison 01 Albumin or PPF vs Hydroxyethyl Starch, Outcome 02 Blood/red cells
transfused (skewed or inadequate data)
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Blood/red cells transfused (skewed or inadequate data)
Study
Boldt 1998 Total units of red blood cells transfused given for each group (Hetastarch 356, albumin 371). No means,
medians or measures of variation given.
Brock 1995 The amount of blood derivaties (’blutderivate’) was given in ml as a mean and standard deviation. In the 10%
starch group the mean was 379 (SD483), in the 6% starch group the mean was 243 (SD 192) and in the 5%
albumin group the mean was 171 (SD236).
Brutocao 1996 Packed red cell transfusion is given in ml/kg. In the HES group the mean is 0.3, the SD 1.3 with a range of 0-
6.4. In the albumin group the mean is 1.1 the SD 3.7 and the range 0-13.1
Claes 1992 Blood transfused is not recorded. Authors say “none of the patients lost an abnormally large quantity of blood
or experienced a clinically perceptible coagulation disorder.”
Diehl 1982 Eighteen percent (n=5) of the albumin group and 15% (n=5) of the HES group received banked blood during
their stay. Blood transfused is recorded as mean number of units per person. In the albumin group this is 0.37
unit per person and in the HES group this is 0.36 unit per person.
Falk 1988 Packed red blood cells transfused at 24 hours is given in mls. The albumin group received a mean of 375 with
a standard error of 244 and the HES group received a mean of 700 with a standard error of 228.
Gallagher 1985 Amount of blood products transfused post operatively was given as a mean in mls with the SEM. For the
albumin group the mean was 560 mls (SEM 149.2) and for the starch group the mean was 566 mls (SEM
72.6).
Gold 1990 Packed red blood cells is given in units. The albumin group received a mean of 2.05 and the HES group
received a mean of 2.50.
Hiippala 1995 Amount of red cell concentrates transfused was given as a mean and standard deviation of ml/kgBW. For
albumin the mean was 20 (SD 14), for 4% HES the mean was 20 (SD 14) and for 6% HES the mean was 25
(SD 17).
Kirklin 1984 The amount of red cells given up to the first 24 hours post op is recorded. In the HES group the mean is 430
with a standard error of 90, and in the albumin group the mean is 440 with a standard error of 76
London 1989 Total post op blood transfused is given in mls. in the Albumin group the figures are given as 838 (630) and
the HES group 894 (600). It does not report what the figures represent (they may be mean and SD). Intra-
operatively the blood given in the albumin group was 400 (346) and in the HES group 336 (400).
Mastroianni 1994 The mean of packed red cells given was recorded in mls. For pentastarch the mean was 167 and for albumin
it was 234. Another figure was given 163 for pentasarch and 148 for albumin but it was not clear what this
represented.
Moggio 1983 There was no data on amount of blood transfused.
Munsch 1988 amount of whole blood transfused was given as a median volume. For the albumin group it was 830 mls (260-
1800), and for the HES group it was 830 mls (50-1840).
Prien 1990 The mean and standard error for the amount of packed red cells given was recorded. For the albumin group
the mean was 1.2 with a standard error of 0.7. In the HES group the mean was 1.8 with a standard error of
0.7.
Rackow 1983 Total amount of blood transfused was given in mls at the end of the maintenance period. For the albumin
group the mean was 363.9 (SEM 186) and for the starch group the mean was 757.1 (SEM 201).
Rackow 1989 No data on units transfused. The authors say “there was no evidence of clinical bleeding”.
Shatney 1983 The amount of red blood cells transfused was given in a graphical form not figures.
Vogt 1994 Amount of EK given was recorded as a mean and standard deviation of the mls given. For the albumin group
it was 1138 (SD 763.5), and for the HES group it was 944.4 (SD 466.2).
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Vogt 1996 The mean and standard deviation of packed red blood cells transfused was given for the end of surgery and at
6 hours. For the albumin group at the end of surgery the mean was 798 (SD 1147) and at 6 hrs it was 1333
(SD 1399). For the HES group at the end of surgery the mean was 763 (SD 923), and at 6 hrs the mean was
1538 (SD 1074).
Vogt 1999 During surgery the patients in the HES group Amount of packed red blood cells was given as means with
standard deviations. In the HES grp the mean was 1510 ml (SD 765) and in the albumin group the mean
was 1410 ml (SD 946)
von Sommoggy 1990 The trialists report ’no increased bleeding in the HES group’.
Analysis 02.01. Comparison 02 Albumin or PPF vs Gelatin, Outcome 01 Death
Review: Colloid solutions for fluid resuscitation
Comparison: 02 Albumin or PPF vs Gelatin
Outcome: 01 Death
Study Albumin or PPF Gelatin Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
x Karanko 1987 0/15 0/12 0.0 Not estimable
Stockwell 1992 45/226 50/249 100.0 0.99 [ 0.69, 1.42 ]
x Tollofsrud 1995 0/10 0/10 0.0 Not estimable
x Wahba 1996 0/10 0/10 0.0 Not estimable
Total (95% CI) 261 281 100.0 0.99 [ 0.69, 1.42 ]
Total events: 45 (Albumin or PPF), 50 (Gelatin)
Test for heterogeneity: not applicable
Test for overall effect z=0.05 p=1
0.1 0.2 0.5 1 2 5 10
Albumin or PPF Gelatin
Analysis 02.02. Comparison 02 Albumin or PPF vs Gelatin, Outcome 02 Blood/red cells transfused (skewed
or inadequate data)
Blood/red cells transfused (skewed or inadequate data)
Study
Stockwell 1992 The volume of blood products given was recorded as a mean with the range also given. In the albumin group the
mean was 1.45 1 (range 1 0-29) and in the haemacell group the mean was 1.39 1 (range 0-66).
Tollofsrud 1995 The amount of erthrocytes given was recorded as a mean and standard deviation. In the albumin group the mean
was 240 (SD 310), and in the polygeline group the mean was 490 (SD 548).
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Analysis 03.01. Comparison 03 Albumin or PPF vs Dextran, Outcome 01 Death
Review: Colloid solutions for fluid resuscitation
Comparison: 03 Albumin or PPF vs Dextran
Outcome: 01 Death
Study Albumin or PPF Dextran Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
x Karanko 1987 0/15 0/10 0.0 Not estimable
x Lisander 1996 0/20 0/20 0.0 Not estimable
x Tollofsrud 1995 0/10 0/10 0.0 Not estimable
Total (95% CI) 45 40 0.0 Not estimable
Total events: 0 (Albumin or PPF), 0 (Dextran)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Albumin or PPF Dextran
Analysis 03.02. Comparison 03 Albumin or PPF vs Dextran, Outcome 02 Blood/red cells transfused (skewed
or inadequate data)
Blood/red cells transfused (skewed or inadequate data)
Study
Hedstrand 1987 The perioperative and postoperative amount of red blood cells transfused was reported as a mean and standard
deviation of units given. For the plasma group the mean was 5.2 (SD 4.8), and for the dextran group the mean was
5.8 (SD 4.4).
Hiippala 1995 Amount of red cell concentrates transfused was given as a mean and standard deviation of ml/kgBW. For albumin
the mean was 20 (SD 14) and for dextran the mean was 19 (12).
Lisander 1996 Total red blood cells transfused is given. For the albumin group the mean is 2.3 and the standard deviation 1.6,
in the Dextran group the mean is 3.8 with a standard deviation of 2.4. Red cells autotransfused is also given 312
(184) in the albumin group and 383 (259) in the dextran group.
Tollofsrud 1995 Erythrocytes given was recorded as mean and standard deviation. The mean for the albumin group was 240 (SD
310), and the mean for the dextran group was 390 (SD 417).
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Analysis 04.01. Comparison 04 Modified Gelatin vs Hydroxyethyl starch, Outcome 01 Death
Review: Colloid solutions for fluid resuscitation
Comparison: 04 Modified Gelatin vs Hydroxyethyl starch
Outcome: 01 Death
Study Gelatin Hydroxyethyl starch Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Allison 1999 0/21 1/24 1.7 0.38 [ 0.02, 8.83 ]
Asfar 2000 12/18 10/16 13.0 1.07 [ 0.65, 1.76 ]
Beards 1994 6/15 5/13 6.6 1.04 [ 0.41, 2.62 ]
Berard 1995 31/153 31/146 38.9 0.95 [ 0.61, 1.49 ]
x Beyer 1997 0/22 0/19 0.0 Not estimable
Boldt 2000 1/50 3/100 2.5 0.67 [ 0.07, 6.25 ]
Boldt 2001 0/25 1/50 1.2 0.65 [ 0.03, 15.50 ]
Haisch 2001a 1/21 1/21 1.2 1.00 [ 0.07, 14.95 ]
x Haisch 2001b 0/21 0/21 0.0 Not estimable
Huttner 2000 1/20 1/40 0.8 2.00 [ 0.13, 30.34 ]
Schortgen 2001 29/64 28/65 34.1 1.05 [ 0.71, 1.55 ]
Total (95% CI) 430 515 100.0 1.00 [ 0.78, 1.28 ]
Total events: 81 (Gelatin), 81 (Hydroxyethyl starch)
Test for heterogeneity chi-square=1.00 df=8 p=1.00 I² =0.0%
Test for overall effect z=0.03 p=1
0.1 0.2 0.5 1 2 5 10
Gelatin Hydroxyethyl starch
Analysis 04.02. Comparison 04 Modified Gelatin vs Hydroxyethyl starch, Outcome 02 Blood/red cells
transfused (skewed or inadequate data)
Blood/red cells transfused (skewed or inadequate data)
Study
Allison 1999 The mean volume of PRBC transfused is given for each day up to and including the 5th day. For the first post-op
day the HES group received a total of 3,067 ml of packed red blood cells and the Gelatine group received 2,643 ml
of packed red blood cells.
Berard 1995 Blood transfused is given in units, 2.6 units for the gel group and 2.5 units for the Hydroxyethyl starch group
(presumably this figure is mean).
Beyer 1997 Blood transfused is given in graphical form and not figures.
Boldt 2000 The amount of PRBC transfused is given as the total number of units for each group.
By the first post operative day the number of units of packed red blood cells transfused was:
HES 70 - 38 units
HES 200 - 40 units
Gelatin - 44 units
Boldt 2001 The amount of PRBC transfused is given as the total number of units for each group.
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Blood/red cells transfused (skewed or inadequate data) (Continued )
Study
By the first post operative day the number of units of packed red blood cells transfused was:
HES 200 18 units
HES 130 16 units
Gelatin 18 units
Carli 2000 The amount of PRBC transfused is given as the total number of units for each group.
1 unit of blood was given in the gel group and no units of blood were given in the starch group.
Haisch 2001a The amount of PRBC and FFP transfused is given as the total number of units for each group.
PRBC
Gelatine = 16 units
Starch = 20 units
FFP
Gelatin = 6
Starch = 8
Haisch 2001b The amount of PRBC and FFP transfused is given as the total number of units for each group.
PRBC
Gelatin = 17
Starch = 14
FFP
Gelatin = 12
Starch = 12
Huttner 2000 The amount of PRBC transfused is given as the total number of units for each group.
Units of PRBC were as follows:
HES 51
Gelatin 29
Analysis 05.01. Comparison 05 Modified Gelatin vs Dextran, Outcome 01 Death
Review: Colloid solutions for fluid resuscitation
Comparison: 05 Modified Gelatin vs Dextran
Outcome: 01 Death
Study Gelatin Dextran Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
x Karanko 1987 0/12 0/10 0.0 Not estimable
x Tollofsrud 1995 0/10 0/10 0.0 Not estimable
Total (95% CI) 22 20 0.0 Not estimable
Total events: 0 (Gelatin), 0 (Dextran)
Test for heterogeneity: not applicable
Test for overall effect: not applicable
0.1 0.2 0.5 1 2 5 10
Gelatin Dextran
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Analysis 05.02. Comparison 05 Modified Gelatin vs Dextran, Outcome 02 Blood/red cells transfused (skewed
or inadequate data)
Blood/red cells transfused (skewed or inadequate data)
Study
Tollofsrud 1995 Erythrocytes given was recorded as mean and standard deviation. The mean in the polygeline group was 490 (SD
548), and the mean in the dextran group was 390 (SD 417).
Analysis 06.02. Comparison 06 Hydroxyethyl starch vs Dextran, Outcome 02 Blood/red cells transfused
(skewed or inadequate data)
Blood/red cells transfused (skewed or inadequate data)
Study
Hiippala 1995 Amount of red cell concentrates transfused was given as a mean and standard deviation of ml/kgBW. For dextran the
mean was 19 (SD 12), for 4% starch the mean was 20 (SD 14) and for 6% starch the mean was 25 (SD 17).
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